Interim Phase IIa Results for Spiegelmer ® Olaptesed Pegol (NOX-A12) in CLL ... Business Wire (press release) In the first study, olaptesed was administered to relapsed chronic lymphocytic leukemia (CLL) patients in combination with bendamustine and rituximab. In the second study, olaptesed was combined with bortezomib and dexamethasone in patients with ... |
